Advertisement

Rapidly Progressive Glomerulonephritis

  • Lavjay Butani
Chapter

Abstract

Rapidly progressive glomerulonephritis is rare in children and adolescents and is seen predominantly in the context of immune complex-mediated diseases. Children often present with non-specific signs and symptoms and may deteriorate rapidly, with the development of alveolar hemorrhage. Since early diagnosis and treatment are critical in improving outcomes, the care of these children should be performed by multidisciplinary teams that have the requisite experience. Serologic testing and renal biopsy are critical to guide therapy; however, therapy should not wait for diagnostic confirmation due to risk of disease progression. While the mortality associated with rapidly progressive glomerulonephritis has declined, outcomes remain suboptimal.

Keywords

Immune complex Immunosuppression Pediatric Outcomes Anti-neutrophilic cytoplasmic antibody Anti-glomerular basement membrane antibody 

References

  1. 1.
    Miller MN, Baumal R, Poucell S, Steele BT. Incidence and prognostic importance of glomerular crescents in renal diseases of childhood. Am J Nephrol. 1984;4(4):244–7.CrossRefGoogle Scholar
  2. 2.
    A clinico-pathologic study of crescentic glomerulonephritis in 50 children. A report of the southwest pediatric nephrology study group. Kidney Int. 1985;27(2):450–8.Google Scholar
  3. 3.
    Little MA, Pusey CD. Rapidly progressive glomerulonephritis: current and evolving treatment strategies. J Nephrol. 2004;17(Suppl 8):S10–9.PubMedGoogle Scholar
  4. 4.
    Khalighi MA, Wang S, Henriksen KJ, Bock M, Keswani M, Chang A, et al. Pauci-immune glomerulonephritis in children: a clinicopathologic study of 21 patients. Pediatr Nephrol. 2015;30(6):953–9.CrossRefGoogle Scholar
  5. 5.
    Rajagopala S, Parameswaran S, Ajmera JS, Ganesh RN, Katrevula A. Diffuse alveolar hemorrhage in IgA nephropathy: case series and systematic review of the literature. Int J Rheum Dis. 2017;20(1):109–21.CrossRefGoogle Scholar
  6. 6.
    Shenoy M, Ognjanovic MV, Coulthard MG. Treating severe Henoch-Schonlein and IgA nephritis with plasmapheresis alone. Pediatr Nephrol. 2007;22(8):1167–71.CrossRefGoogle Scholar
  7. 7.
    Mara-Koosham G, Stoltze K, Aday J, Rendon P. Pulmonary renal syndrome after streptococcal pharyngitis: a case report. J Investig Med High Impact Case Rep. 2016;4(2):1–4. 2324709616646127Google Scholar
  8. 8.
    Harada T, Ozono Y, Miyazaki M, Sasaki O, Miyazaki K, Abe K, et al. Plasmapheresis in the treatment of rapidly progressive glomerulonephritis. Ther Apher. 1997;1(4):366–9.CrossRefGoogle Scholar
  9. 9.
    Stratta P, Canavese C, Fenoglio R, Priolo G, Grillo A, Aimo G, et al. Dual effect of methylprednsolone pulses on apoptosis of peripheral leukocytes in patients with renal diseases. Int J Immunopathol Pharmacol. 2006;19(3):647–59.CrossRefGoogle Scholar
  10. 10.
    Bayat A, Kamperis K, Herlin T. Characteristics and outcome of Goodpasture’s disease in children. Clin Rheumatol. 2012;31(12):1745–51.CrossRefGoogle Scholar
  11. 11.
    Gittins N, Basu A, Eyre J, Gholkar A, Moghal N. Cerebral vasculitis in a teenager with Goodpasture’s syndrome. Nephrol Dial Transplant. 2004;19(12):3168–71.CrossRefGoogle Scholar
  12. 12.
    Kim JY, Ahn KJ, Jung JI, Jung SL, Kim BS, Hahn ST. Imaging findings of central nervous system vasculitis associated with Goodpasture’s syndrome: a case report. Korean J Radiol. 2007;8(6):545–7.CrossRefGoogle Scholar
  13. 13.
    Greco A, Rizzo MI, De Virgilio A, Gallo A, Fusconi M, Pagliuca G, et al. Goodpasture’s syndrome: a clinical update. Autoimmun Rev. 2015;14(3):246–53.CrossRefGoogle Scholar
  14. 14.
    Fisher M, Pusey CD, Vaughan RW, Rees AJ. Susceptibility to anti-glomerular basement membrane disease is strongly associated with HLA-DRB1 genes. Kidney Int. 1997;51(1):222–9.CrossRefGoogle Scholar
  15. 15.
    Shah MK, Hugghins SY. Characteristics and outcomes of patients with Goodpasture’s syndrome. South Med J. 2002;95(12):1411–8.CrossRefGoogle Scholar
  16. 16.
    Donaghy M, Rees AJ. Cigarette smoking and lung haemorrhage in glomerulonephritis caused by autoantibodies to glomerular basement membrane. Lancet. 1983;2(8364):1390–3.CrossRefGoogle Scholar
  17. 17.
    Bombassei GJ, Kaplan AA. The association between hydrocarbon exposure and anti-glomerular basement membrane antibody-mediated disease (Goodpasture’s syndrome). Am J Ind Med. 1992;21(2):141–53.CrossRefGoogle Scholar
  18. 18.
    Meyer D, Coles A, Oyuela P, Purvis A, Margolin DH. Case report of anti-glomerular basement membrane disease following alemtuzumab treatment of relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2013;2(1):60–3.CrossRefGoogle Scholar
  19. 19.
    Jayne DR, Marshall PD, Jones SJ, Lockwood CM. Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis. Kidney Int. 1990;37(3):965–70.CrossRefGoogle Scholar
  20. 20.
    Srivastava A, Rao GK, Segal PE, Shah M, Geetha D. Characteristics and outcome of crescentic glomerulonephritis in patients with both antineutrophil cytoplasmic antibody and anti-glomerular basement membrane antibody. Clin Rheumatol. 2013;32(9):1317–22.CrossRefGoogle Scholar
  21. 21.
    Poddar B, Singhal S, Azim A, Gulati S, Baronia A. Goodpasture’s syndrome in children. Saudi J Kidney Dis Transpl. 2010;21(5):935–9.PubMedGoogle Scholar
  22. 22.
    Levy JB, Turner AN, Rees AJ, Pusey CD. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med. 2001;134(11):1033–42.CrossRefGoogle Scholar
  23. 23.
    Kotanko P, Pusey CD, Levy JB. Recurrent glomerulonephritis following renal transplantation. Transplantation. 1997;63(8):1045–52.CrossRefGoogle Scholar
  24. 24.
    Chapter 14: anti-glomerular basement membrane antibody glomerulonephritis. Kidney Int Suppl (2011). 2012;2(2):240–2.Google Scholar
  25. 25.
    Touzot M, Poisson J, Faguer S, Ribes D, Cohen P, Geffray L, et al. Rituximab in anti-GBM disease: a retrospective study of 8 patients. J Autoimmun. 2015;60:74–9.CrossRefGoogle Scholar
  26. 26.
    Garcia-Canton C, Toledo A, Palomar R, Fernandez F, Lopez J, Moreno A, et al. Goodpasture’s syndrome treated with mycophenolate mofetil. Nephrol Dial Transplant. 2000;15(6):920–2.CrossRefGoogle Scholar
  27. 27.
    Bjerre A, Hogasen K, Grotta J, Scott H, Tangeraas T, Dorje C. Rescue of kidney function in a toddler with anti-GBM nephritis. Clin Kidney J. 2012;5(6):584–6.CrossRefGoogle Scholar
  28. 28.
    Clark WF, Huang SS, Walsh MW, Farah M, Hildebrand AM, Sontrop JM. Plasmapheresis for the treatment of kidney diseases. Kidney Int. 2016;90(5):974–84.CrossRefGoogle Scholar
  29. 29.
    Shah S, Havill J, Rahman MH, Geetha D. A historical study of American patients with anti-neutrophil cytoplasmic antibody negative pauci-immune glomerulonephritis. Clin Rheumatol. 2016;35(4):953–60.CrossRefGoogle Scholar
  30. 30.
    Kouri AM, Andreoli SP. Clinical presentation and outcome of pediatric ANCA-associated glomerulonephritis. Pediatr Nephrol. 2017;32(3):449–55.CrossRefGoogle Scholar
  31. 31.
    Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 Revised International Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1–11.CrossRefGoogle Scholar
  32. 32.
    Berden AE, Ferrario F, Hagen EC, Jayne DR, Jennette JC, Joh K, et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol. 2010;21(10):1628–36.CrossRefGoogle Scholar
  33. 33.
    Tanna A, Pusey CD. The histopathological classification of ANCA-associated glomerulonephritis comes of age. J Rheumatol. 2017;44(3):265–7.CrossRefGoogle Scholar
  34. 34.
    Noone DG, Twilt M, Hayes WN, Thorner PS, Benseler S, Laxer RM, et al. The new histopathologic classification of ANCA-associated GN and its association with renal outcomes in childhood. Clin J Am Soc Nephrol. 2014;9(10):1684–91.CrossRefGoogle Scholar
  35. 35.
    Plumb LA, Oni L, Marks SD, Tullus K. Paediatric anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: an update on renal management. Pediatr Nephrol. 2018; 33(1):25–39.  https://doi.org/10.1007/s00467-016-3559-2. Epub 2017 Jan 6.CrossRefGoogle Scholar
  36. 36.
    Rottem M, Fauci AS, Hallahan CW, Kerr GS, Lebovics R, Leavitt RY, et al. Wegener granulomatosis in children and adolescents: clinical presentation and outcome. J Pediatr. 1993;122(1):26–31.CrossRefGoogle Scholar
  37. 37.
    Akikusa JD, Schneider R, Harvey EA, Hebert D, Thorner PS, Laxer RM, et al. Clinical features and outcome of pediatric Wegener’s granulomatosis. Arthritis Rheum. 2007;57(5):837–44.CrossRefGoogle Scholar
  38. 38.
    Gendelman S, Zeft A, Spalding SJ. Childhood-onset eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome): a contemporary single-center cohort. J Rheumatol. 2013;40(6):929–35.CrossRefGoogle Scholar
  39. 39.
    Ozen S, Pistorio A, Iusan SM, Bakkaloglu A, Herlin T, Brik R, et al. EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. Ann Rheum Dis. 2010;69(5):798–806.CrossRefGoogle Scholar
  40. 40.
    Cabral DA, Canter DL, Muscal E, Nanda K, Wahezi DM, Spalding SJ, et al. Comparing presenting clinical features in 48 children with microscopic polyangiitis to 183 children who have granulomatosis with polyangiitis (Wegener’s): an ARChiVe cohort study. Arthritis Rheum. 2016;68(10):2514–26.CrossRefGoogle Scholar
  41. 41.
    Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic antibodies. Lancet. 2006;368(9533):404–18.CrossRefGoogle Scholar
  42. 42.
    Schmitt WH, van der Woude FJ. Clinical applications of antineutrophil cytoplasmic antibody testing. Curr Opin Rheumatol. 2004;16(1):9–17.CrossRefGoogle Scholar
  43. 43.
    Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18(7):2180–8.CrossRefGoogle Scholar
  44. 44.
    Walsh M, Casian A, Flossmann O, Westman K, Hoglund P, Pusey C, et al. Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int. 2013;84(2):397–402.CrossRefGoogle Scholar
  45. 45.
    de Lind van Wijngaarden RA, Hauer HA, Wolterbeek R, Jayne DR, Gaskin G, Rasmussen N, et al. Chances of renal recovery for dialysis-dependent ANCA-associated glomerulonephritis. J Am Soc Nephrol. 2007;18(7):2189–97.CrossRefGoogle Scholar
  46. 46.
    Chapter 13: Pauci-immune focal and segmental necrotizing glomerulonephritis. Kidney Int Suppl (2011). 2012;2(2):233–9.Google Scholar
  47. 47.
    Hotta O, Ishida A, Kimura T, Taguma Y. Improvements in treatment strategies for patients with antineutrophil cytoplasmic antibody-associated rapidly progressive glomerulonephritis. Ther Apher Dial. 2006;10(5):390–5.CrossRefGoogle Scholar
  48. 48.
    Walters G, Willis NS, Craig JC. Interventions for renal vasculitis in adults. Cochrane Database Syst Rev. 2015;(9):CD003232.Google Scholar
  49. 49.
    Guillevin L, Cohen P, Mahr A, Arene JP, Mouthon L, Puechal X, et al. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum. 2003;49(1):93–100.CrossRefGoogle Scholar
  50. 50.
    Hogan SL, Falk RJ, Chin H, Cai J, Jennette CE, Jennette JC, et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med. 2005;143(9):621–31.CrossRefGoogle Scholar
  51. 51.
    Haubitz M, Schellong S, Gobel U, Schurek HJ, Schaumann D, Koch KM, et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum. 1998;41(10):1835–44.CrossRefGoogle Scholar
  52. 52.
    Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221–32.CrossRefGoogle Scholar
  53. 53.
    Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med. 2013;369(5):417–27.CrossRefGoogle Scholar
  54. 54.
    Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211–20.CrossRefGoogle Scholar
  55. 55.
    Jones RB, Furuta S, Tervaert JW, Hauser T, Luqmani R, Morgan MD, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Ann Rheum Dis. 2015;74(6):1178–82.CrossRefGoogle Scholar
  56. 56.
    McGregor JG, Hogan SL, Kotzen ES, Poulton CJ, Hu Y, Negrete-Lopez R, et al. Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis. Nephrol Dial Transplant. 2015;30(Suppl 1):i123–31.CrossRefGoogle Scholar
  57. 57.
    Han F, Liu G, Zhang X, Li X, He Q, He X, et al. Effects of mycophenolate mofetil combined with corticosteroids for induction therapy of microscopic polyangiitis. Am J Nephrol. 2011;33(2):185–92.CrossRefGoogle Scholar
  58. 58.
    Hu W, Liu C, Xie H, Chen H, Liu Z, Li L. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol Dial Transplant. 2008;23(4):1307–12.CrossRefGoogle Scholar
  59. 59.
    Pepper RJ, Chanouzas D, Tarzi R, Little MA, Casian A, Walsh M, et al. Intravenous cyclophosphamide and plasmapheresis in dialysis-dependent ANCA-associated vasculitis. Clin J Am Soc Nephrol. 2013;8(2):219–24.CrossRefGoogle Scholar
  60. 60.
    Jayne DR, Chapel H, Adu D, Misbah S, O’Donoghue D, Scott D, et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM. 2000;93(7):433–9.CrossRefGoogle Scholar
  61. 61.
    Lockwood CM, Thiru S, Stewart S, Hale G, Isaacs J, Wraight P, et al. Treatment of refractory Wegener’s granulomatosis with humanized monoclonal antibodies. QJM. 1996;89(12):903–12.CrossRefGoogle Scholar
  62. 62.
    Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349(1):36–44.CrossRefGoogle Scholar
  63. 63.
    Hiemstra TF, Walsh M, Mahr A, Savage CO, de Groot K, Harper L, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA. 2010;304(21):2381–8.CrossRefGoogle Scholar
  64. 64.
    Pagnoux C, Mahr A, Hamidou MA, Boffa JJ, Ruivard M, Ducroix JP, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359(26):2790–803.CrossRefGoogle Scholar
  65. 65.
    Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaitre O, Cohen P, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371(19):1771–80.CrossRefGoogle Scholar
  66. 66.
    Westman KW, Bygren PG, Olsson H, Ranstam J, Wieslander J. Relapse rate, renal survival, and cancer morbidity in patients with Wegener’s granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol. 1998;9(5):842–52.PubMedGoogle Scholar
  67. 67.
    Kyndt X, Reumaux D, Bridoux F, Tribout B, Bataille P, Hachulla E, et al. Serial measurements of antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis. Am J Med. 1999;106(5):527–33.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of PediatricsUniversity of California Davis Medical CenterSacramentoUSA

Personalised recommendations